1. Glutamine deprivation triggers NAGK-dependent hexosamine salvage.
- Author
-
Campbell S, Mesaros C, Izzo L, Affronti H, Noji M, Schaffer BE, Tsang T, Sun K, Trefely S, Kruijning S, Blenis J, Blair IA, and Wellen KE
- Subjects
- Animals, Cell Line, Humans, Mice, Mice, Nude, Carcinoma, Pancreatic Ductal metabolism, Glutamine deficiency, Hexosamines metabolism, Pancreatic Neoplasms metabolism, Phosphotransferases (Alcohol Group Acceptor) metabolism
- Abstract
Tumors frequently exhibit aberrant glycosylation, which can impact cancer progression and therapeutic responses. The hexosamine biosynthesis pathway (HBP) produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a major substrate for glycosylation in the cell. Prior studies have identified the HBP as a promising therapeutic target in pancreatic ductal adenocarcinoma (PDA). The HBP requires both glucose and glutamine for its initiation. The PDA tumor microenvironment is nutrient poor, however, prompting us to investigate how nutrient limitation impacts hexosamine synthesis. Here, we identify that glutamine limitation in PDA cells suppresses de novo hexosamine synthesis but results in increased free GlcNAc abundance. GlcNAc salvage via N-acetylglucosamine kinase (NAGK) is engaged to feed UDP-GlcNAc pools. NAGK expression is elevated in human PDA, and NAGK deletion from PDA cells impairs tumor growth in mice. Together, these data identify an important role for NAGK-dependent hexosamine salvage in supporting PDA tumor growth., Competing Interests: SC, CM, LI, HA, MN, BS, TT, KS, ST, SK, JB, KW No competing interests declared, IB IAB is a founder of Proteoform Bio and a paid consultant for Calico, Chimerix, PTC Therapeutics, Takeda Pharmaceuticals, and Vivo Capital., (© 2021, Campbell et al.)
- Published
- 2021
- Full Text
- View/download PDF